




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 477/20, A61K 31/40	A1	(11) International Publication Number: WO 00/06574 (43) International Publication Date: 10 February 2000 (10.02.00)
(21) International Application Number: PCT/EP99/05295 (22) International Filing Date: 23 July 1999 (23.07.99) (30) Priority Data: 98114067.6 28 July 1998 (28.07.98) EP (71)(72) Applicant and Inventor: PFAENDLER, Hans, Rudolf [CH/DE]; Schuler Strasse 26, D-82131 Stockdorf (DE). (74) Agent: SPOTT, Gottfried, G.; Spott & Weinmiller, Sendlinger-Tor-Platz 11, D-80336 München (DE).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: NOVEL C-2 S/O- AND S/N FORMALDEHYDE ACETAL DERIVATIVES OF CARBAPENEM-3-CARBOXYLIC ACIDS AND THEIR USE AS ANTIBIOTICS AND β -LACTAMASE INHIBITORS <div style="text-align: center;">  (1) </div> (57) Abstract <p>The compounds of general formula (I) wherein R¹ denotes hydrogen, hydroxymethyl or 1-hydroxyethyl, R² denotes hydrogen or methyl and R³ denotes a pharmaceutically acceptable group which is bonded to the remaining part of the molecule by an oxygen-carbon single bond or a nitrogen-carbon single bond, and their pharmaceutically acceptable salts, esters and amide derivatives are broad spectrum antibiotics and β-lactamase inhibitors.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Novel C-2 S/O- and S/N Formaldehyde Acetal Derivatives of Carbapenem-3-carboxylic Acids and their Use as Antibiotics and β -Lactamase Inhibitors

5 Description and Background of the Invention

This invention relates to novel 2-S/O- and S/N formaldehyde acetal derivatives of carbapenem-3-carboxylic acids of the general formula I

10



15

I

wherein R^1 denotes hydrogen, hydroxymethyl or 1-hydroxyethyl, R^2 denotes hydrogen or methyl and R^3 denotes a pharmaceutically acceptable group which is bonded to the remaining part of the molecule by an oxygen-carbon single bond or a nitrogen-carbon single bond and which is selected from the group comprising substituted or unsubstituted: alkoxy, alkenyloxy, alkinyloxy, cycloalkoxy, N-heterocyclyl, heterocyclyloxy, heterocyclylcarbonyloxy, heterocyclylthiocarbonyloxy, acyloxy, thioacyloxy, alkoxy carbonyloxy, carbamoyloxy, thiocarbamoyloxy, heterocyclyloxycarbonyloxy, heterocyclyloxythiocarbonyloxy, N-heterocyclyl carbamoyloxy, N-heterocyclylthiocarbamoyloxy, heterocyclylcarbonylamino, heterocyclylthiocarbonylamino, heterocyclyloxycarbonylamino, acylamino, alkoxy carbonylamino, alkoxythiocarbonylamino, thioacylamino, N-heterocyclyl carbamoylamino, N-heterocyclylthiocarbamoylamino, carbamoylamino, thiocarbamoylamino, imidoylamino, guanidino, N-heterocyclyl-alkoxy carbonylamino, N-heterocyclyl-alkylthiocarbonylamino and N-sulfonylamino where the foregoing alkyl, alkenyl, alkynyl, acyl, thioacyl or imidoyl molecule parts contain 1 to 6 carbon atoms and the heterocyclyl moiety is monocyclic or bicyclic and contains 3 to 10 ring atoms, of which one or more are selected from the series comprising: oxygen, sulphur and nitrogen and where the substituents of the above-mentioned groups R^3 may be: alkyl, acyl, thioacyl,

35

heterocyclyl, hydroxyl, hydroxyalkyl, alkoxy, hydroxyalkoxy, aminoalkoxy, amidinoalkoxy, guanidinoalkoxy, acyloxy, heterocyclyloxy, alkylheterocyclyloxy, hydroxyalkylheterocyclyloxy, aminoalkylheterocyclyloxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, carbamoyloxy, alkylcarbamoyloxy, dialkylcarbamoyloxy, thiocarbamoyl, alkylthiocarbamoyl, dialkylthiocarbamoyl, thiocarbamoyloxy, alkylthiocarbamoyloxy, dialkylthiocarbamoyloxy, mercapto, alkylthio, hydroxyalkylthio, aminoalkylthio, monoalkylaminoalkylthio, dialkylaminoalkylthio, amidinoalkylthio, acylthio, heterocyclylthio, alkylheterocyclylthio, hydroxyalkylheterocyclylthio, aminoalkylheterocyclylthio, carbamoylthio, monoalkylcarbamoylthio, dialkylcarbamoylthio, thiocarbamoylthio, alkylthiocarbamoylthio, dialkylcarbamoylthio, amino, monoalkylamino, hydroxyalkylamino, aminoalkylamino, dialkylamino, oxo, oximino, or alkylimino, imidoalkylamino, alkylimidoalkylamino, dialkylimidoalkylamino, tetraalkylammonium, cycloalkylamino, heterocyclylamino, alkylheterocyclylamino, heterocyclylcarbonylamino, alkylheterocyclylcarbonylamino, acylamino, amidino, monoalkylamidino, dialkylamidino, guanidino, alkylguanidino, dialkylguanidino, carbamoylamino, thiocarbamoylamino, alkylcarbamoylamino, thiocarbamoylamino, alkylthiocarbamoylamino, nitro, chlorine, bromine, fluorine, iodine, azido, cyano, alkylsulphinyl, alkylsulphonyl, sulphonamido, sulphamoyloxy, alkylsulphamoyloxy, alkylsulphonyloxy or sulpho, sulphoxy, carboxamido, N-monoalkylcarboxamido, N,N-dialkylcarboxamido or carboxy, where the substituents, independently of one another, occur once or several times and their alkyl moiety contains 1 to 6 carbon atoms, and where the heterocyclic moiety is monocyclic or bicyclic and contains 3 to 10 ring atoms, of which one or more are selected from the series comprising: oxygen, sulphur and nitrogen, which compounds and their pharmaceutically acceptable salts, esters and amide derivatives are useful as antibiotics and as β -lactamase inhibitors.

Pharmaceutically acceptable groups R^3 , which are bonded via an oxygen-carbon single bond or a nitrogen-carbon single bond are groups as are customary, for example, in the field β -lactam antibiotics or β -lactamase inhibitors. Such groups are found, for example, in M.S. Sassiver, A. Lewis in „Advances in Applied Microbiology“, Ed. D. Perlman, Academic Press N.Y. (1970) or in many patents, e. g. US Pat. 5,096,899.

The term „pharmaceutically acceptable salt“ as used herein and in the claims, includes non-toxic acid and base salts and the salts of zwitterionic species. Salts with

a base include inorganic salts such as sodium, potassium, magnesium and calcium, or ammonium and salts with non-toxic amines such as trialkylamines, alkanolamines, arginine or cyclic amines such as piperazine, procaine and other amines, which have been used to form salts of carboxylic acids. Salts with an acid include inorganic acid salts such as hydrochloride, sulfate, phosphate and the like and organic acid salts such as acetate, maleate, citrate, succinate, ascorbate, lactate, fumarate, tartrate and oxalate and other organic salts with acids which have been used to form salts with amines.


10 The pharmaceutically acceptable esters and amide derivatives as used herein, serve as prodrugs by being hydrolyzed in the body to yield the antibiotic per se. They are preferably administered orally since hydrolysis occurs principally under the influence of the digestive enzymes. Parenteral administration may be used in some instances where hydrolysis occurs in the blood. Examples of pharmaceutically acceptable esters and amide derivatives include physiologically hydrolyzable esters and amides known and used in the penicillin and cephalosporin fields as, e. g. in Advances in Drug Res. 17, 197 (1988). Such esters and amide derivatives are prepared by conventional techniques known in the art.

20 The compounds according to the invention have several asymmetric centers and can thus exist in several stereochemical forms. The invention includes the mixture of isomers and the individual stereoisomers. The most preferred compounds of formula I have the 1R, 5S and 6S configuration of the substituted carbapenem nucleus and the 1'R or the 1'S configuration of the 6-(1-hydroxyethyl) side chain.


25 Additionally, asymmetric carbon atoms can be included in the substituent R^3 . The invention includes the compounds having the R and S configuration in the substituent R^3 .

This invention also relates to processes for the preparation of compounds (I), pharmaceutical compositions comprising such compounds and to methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated.

The terminology for compounds of this class may either be based upon the root name „carbapenem“ which employs a trivial and simple system of nomenclature (used in the general description). Alternatively, these compounds can also be described by the nomenclature according to the Chemical Abstract system (bicyclo-nomenclature) which is more appropriate to describe individual compounds of this family. Therefore the Chemical Abstract nomenclature is used within the Example Section.



carbapenem-nomenclature

nomenclature
according to Chemical Abstracts


The classical β -lactam antibiotics such as the penicillins or the cephalosporins have partly become ineffective in the therapy of infectious diseases because of bacterial resistance. Besides the natural resistance of certain bacteria, many strains of pathogenic microorganisms have acquired resistance with continuous use of antibiotics on a large scale. Thus, most species of *Staphylococcus aureus* have become resistant against the penicillins and many Gram-negative bacteria such as *Enterobacter cloacae*, *Pseudomonas aeruginosa* or even *Escherichia coli* have acquired resistance against the cephalosporins.

Consequently, there is a continuing need for new antibiotics. This search is particularly acute for antibiotics which have a wide spectrum or are orally active.

Within the β -lactams, the carbapenems represent the most effective class of compounds. These are active also against most penicillin- and cephalosporin resistant strains. However, the carbapenems currently used, are administered parenterally because they do not have sufficient oral activity. The lack of oral activity is known in the art and described, e. g. in *Infection* 14, (1986), suppl. 2, S 115.

It is an objective of the present invention to provide a novel class of carbapenem antibiotics having a very broad antibacterial spectrum and being orally active.

The compounds of the above formula I are conveniently prepared in accordance with the following equation:



Thus, the intermediate 3 is prepared by reaction of the starting material 1, containing a leaving group X, wherein R¹ and R² are defined as above-mentioned, with a HS/O- or a HS/N-formaldehyde acetal HS-CH₂-R³, preferably in presence of a base, wherein R³ is defined as above-mentioned.

Because of the high reactivity of the HS/O- or HS/N-formaldehyde acetals, especially in presence of a base, the leaving group of X is not very critical. In fact, the reaction can be carried out by using a great variety of leaving groups X. Examples for such leaving groups X are alkoxy groups such as methoxy, alkylsulfonyloxy or arylsulfonyloxy groups such as methylsulfonyloxy, trifluormethylsulfonyloxy and p-toluenesulfonyloxy or dialkoxyphosphinoyloxy or or diaryloxyphosphinoyloxy groups such as dimethoxyphosphinoyloxy or preferably diphenoxylphosphinoyloxy.

30

Examples for the preparation of starting materials 1 are described in Heterocycles **1984**, **21**, 29-40, or in Tetrahedron Lett. **1980**, **21**, 4221-4224.

Inorganic or organic bases can be used in the process 1→3, for example potassium or caesium carbonate or tertiary amines such as triethylamine and pyridine or preferably hindered bases such as diisopropylethylamine and 2,6-dimethylpyridine.

35

Because of the high reactivity of the above-mentioned HS/O- or HS/N-formaldehyde acetals the reaction temperature can be varied within a large range. Preferably the process 1→3 is carried out between -70 °C and room temperature. A unpolar or polar solvent such as methylene chloride or acetonitrile, or preferably N,N-

5 dimethylformamide, is suitable. The process 1→3 can also be carried out using phase transfer conditions, for example those using water, an unpolar solvent such as carbon tetrachloride or methylene chloride and a phase transfer catalyst such as tetrabutylammonium bromide.

10 The process 1→3 can also be carried out by using a preformed salt, preferably an alkali, earth alkali or tetraalkylammonium salt of the HS/O- or HS/N- formaldehyde acetals 2. With the inorganic salts, the process 1→3 is preferably carried out without additional base in a polar solvent, for example N,N-dimethylformamide. With the more soluble tetraalkylammonium salts, a less polar solvent such as tetrahydrofuran is

15 preferable.

The protecting groups Y in the starting material 1 and in the intermediate 3 are easily removable radicals which are known per se, as are usually used for the purpose in organic synthesis. Protecting groups of this type are found, for example in Gunda I.

20 Georg „The Organic Chemistry of β -Lactams“, VCH Publishers UK, Cambridge, 1993, pp. 23- 29.

Within the deprotection process 3→I, the free carboxylic acid or the corresponding inorganic salts are generated. In special cases it is possible that a selected

25 substituent R³ can be altered simultaneously during the process 3→I.

An example for such special processes is the simultaneous reduction of a 2-azidoethoxy group R³ to a 2-aminoethoxy group during the deprotection of 3 (Y = p-nitrobenzyl) by a catalytic hydrogenolysis.

30 A prerequisite for the preparation of the compounds of structural formula I was the availability of the corresponding HS/O- and HS/N-formaldehyde acetals 2. We found that the classes of simple HS/O formaldehyde acetals (R³ = unsubstituted alkoxy) and HS/N-formaldehyde acetals (R³ = unsubstituted acylamino), were not known by prior art. Therefore it was also an object of the present invention to prepare the suitable


35 novel formaldehyde derivatives 2.

2-Alkoxyalkylthiocarbapenems have been reported in EP 0 010 317. They were prepared from known unsubstituted 2-alkoxyalkanethiols as reagents. However, the 2-alkoxymethylthiocarbapenems were not accessible by this method since the required reagents, the HS/O formaldehyde acetals (2, R^3 = unsubstituted alkoxy) having 1 to 6 carbon atoms in their alkoxy molecular part, was a class of compounds, unknown by prior art. This class of reagents was considered to be too unstable to be of practical value (Houben-Weyl, Methoden der Org. Chemie., Vol. E 14a/1, G. Thieme ed., Stuttgart, N.Y. 1991, p. 793. This report constitutes a prejudice against the above-mentioned 2-alkoxymethanethiols and against the inventive solution leading to 2-alkoxymethylthiocarbapenem-3-carboxylic acids.

Although a compound with b.p. 52 °C/15 mm has been erroneously reported as methoxymethanethiol in the early literature (Chem. Zentralbl. 1912, 1192) we found no later reports of any use of this reagent in Chem. Abstr. Methoxymethanethiol was not accessible using the reported procedure, but had to be prepared on an entirely different (4→6→2 or 5→6→2) route. In fact, true methoxymethanethiol is by far more volatile than the reported compound and has a b.p. of 51 °C at ambient pressure! As the corresponding HS/O formaldehyde acetals were not accessible, 2-alkoxymethylthiocarbapenems I (R^3 = methoxy) were never prepared and therefore not described in Chem. Abstr.

Similarly, the unsubstituted HS/N formaldehyde acetals 2 (R^3 = unsubstituted acylamino) represented an unknown class of compounds. As reagents 2 (R^3 = acylamino) are required in the preparation of acylaminomethylthiocarbapenems I (R^3 = acylamino), the latter were not accessible by prior art either. Consequently, 2-acylaminomethylthiocarbapenems have not been described in Chem. Abstr.

The novel HS/O- or HS/N- formaldehyde acetals 2 are conveniently prepared via the following routes:



10 wherein R^3 is described as above-mentioned. The starting compounds 4 and 5 are known and can be prepared according to procedures known per se or are commercially available, as for example in the case of chloromethyl methyl ether (4, $\text{R}^3 = \text{OCH}_3$) or N-hydroxymethylacetamide (5, $\text{R}^3 = \text{HN-CO-CH}_3$). The process 4 \rightarrow 6 is preferably carried out in a polar or unpolar solvent such as acetonitrile, ether or
 15 chloroform at -70°C to room temperature, the process 5 \rightarrow 6 can also be carried out in a solvent, or preferably, without a solvent (using an excess of thioacetic acid) at -30°C to $+60^\circ\text{C}$. Alternatively, instead of commercially available potassium thioacetate, other alkali or earth alkali thioacetates can be used.

20 The hydrolysis process 6 \rightarrow 2 can be carried out using alkaline or acidic conditions, for example using alkali or earth alkali hydroxides or alkali or earth alkali alkoxides, preferably sodium hydroxide or sodium methoxide in a polar solvent such as water, acetonitrile or methyl alcohol. Suitable acidic conditions in the process 6 \rightarrow 2 use strong acids, preferably hydrogen chloride, in a polar solvent such as water or
 25 methyl alcohol. The hydrolyses are preferably carried out at -30°C to room temperature. The HS/O- or HS/N formaldehyde acetals 2 can be isolated in their free state or as alkali, earth alkali or tetraalkylammonium salts.

As already mentioned, currently used carbapenems do not possess sufficient oral
 30 activity. The oral activity of the compounds I, according to the invention, arises from the novel S/O or S/N formaldehyde acetal groups. Similar derivatives of formaldehyde, i.e. an O/O formaldehyde acetal led to increased oral absorbability with the penicillins, for example with pivaloyloxymethyl esters of penicillins as described in Merck Index, 11th ed. 7484, p. 1193. The strong influence of spacer length of
 35 substituents was reported in the field of cephalosporins (Journ. Antibiot. 1993, 46,

177), where oral bioavailability has become a target of intensive research. In this literature report, a S/S formaldehyde acetal derivative was found to be superior over fourteen other compounds. Unfortunately, because of the unpolar character of the S/S acetal moiety, the activity against *Pseudomonas aeruginosa*, inherent in the class of aminothiazol cephalosporins, was largely reduced.

In the field of carbapenems, oral activity was also reported with 2-S/S formaldehyde acetal derivatives in Eur Pat. Appl. 0 481 511 A2, illustrating that the methylene group is suitable as a spacer between two sulfur atoms, to provide oral activity within this family of antibiotics.

However, no reports about S/O- or N/O formaldehyde acetals have appeared and no data about their oral bioavailability or their antibacterial activity have become known. Compared to the above-mentioned, reported 2-S/S-formaldehyde acetals, the compounds I, according to the invention, are more polar and therefore also active against the clinically important pathogen *Pseudomonas aeruginosa*.

Compared to other reported 2-alkoxyalkylthiocarbapenems, or 2-acylaminoalkylthiocarbapenems, having larger spacer lengths of their alkylene moiety, the compounds I are strongly preferred because of their oral absorbability.

In the general description of the present invention, the group R^1 denotes hydrogen, hydroxymethyl or 1-hydroxyethyl, R^2 denotes hydrogen or methyl and R^3 denotes a pharmaceutically acceptable group, which is bonded to the remaining part of the molecule by an oxygen-carbon single bond or a nitrogen-carbon single bond and which is selected from the group comprising substituted or unsubstituted: alkoxy, alkenyloxy, alkinyloxy, cycloalkoxy, N-heterocyclyl, heterocyclyloxy, heterocyclylcarbonyloxy, heterocyclylthiocarbonyloxy, acyloxy, thioacyloxy, alkoxy carbonyloxy, carbamoyloxy, thiocarbamoyloxy, heterocyclyloxy carbonyloxy, heterocyclyloxythiocarbonyloxy, N-heterocyclyl carbamoyloxy, N-heterocyclylthiocarbamoyloxy, heterocyclyl carbonylamino, heterocyclylthiocarbonylamino, heterocyclyloxy carbonylamino, acylamino, alkoxy carbonylamino, alkoxythiocarbonylamino, thioacylamino, N-heterocyclyl carbamoylamino, N-heterocyclylthiocarbamoylamino, carbamoylamino, thiocarbamoylamino, imidoylamino, guanidino, N-heterocyclyl-alkoxy carbonylamino,

N-heterocyclyl-alkylthiocarbonylamino and N-sulfonylamino where the foregoing alkyl, alkenyl, alkynyl, acyl, thioacyl or imidoyl molecule parts contain 1 to 6 carbon atoms and the heterocyclyl moiety is monocyclic or bicyclic and contains 3 to 10 ring atoms, of which one or more are selected from the series comprising: oxygen, sulphur and nitrogen and where the substituents of the above-mentioned groups R³ may be: alkyl, acyl, thioacyl, heterocyclyl, hydroxyl, hydroxyalkyl, alkoxy, hydroxyalkoxy, aminoalkoxy, amidinoalkoxy, guanidinoalkoxy, acyloxy, heterocyclyloxy, alkylheterocyclyloxy, hydroxyalkylheterocyclyloxy, aminoalkylheterocyclyloxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, carbamoyloxy, alkylcarbamoyloxy, dialkylcarbamoyloxy, thiocarbamoyl, alkylthiocarbamoyl, dialkylthiocarbamoyl, thiocarbamoyloxy, alkylthiocarbamoyloxy, dialkylthiocarbamoyloxy, mercapto, alkylthio, hydroxyalkylthio, aminoalkylthio, monoalkylaminoalkylthio, dialkylaminoalkylthio, amidinoalkylthio, acylthio, heterocyclylthio, alkylheterocyclylthio, hydroxyalkylheterocyclylthio, aminoalkylheterocyclylthio, carbamoylthio, monoalkylcarbamoylthio, dialkylcarbamoylthio, thiocarbamoylthio, alkylthiocarbamoylthio, dialkylcarbamoylthio, amino, monoalkylamino, hydroxyalkylamino, aminoalkylamino, dialkylamino, oxo, oximino, or alkylimino, imidoylamino, alkylimidoylamino, dialkylimidoylamino, tetraalkylammonium, cycloalkylamino, heterocyclylamino, alkylheterocyclylamino, heterocyclylcarbonylamino, alkylheterocyclylcarbonylamino, acylamino, amidino, monoalkylamidino, dialkylamidino, guanidino, alkylguanidino, dialkylguanidino, carbamoylamino, thiocarbamoylamino, alkylcarbamoylamino, thiocarbamoylamino, alkylthiocarbamoylamino, nitro, chlorine, bromine, fluorine, iodine, azido, cyano, alkylsulphinyl, alkylsulphonyl, sulphonamido, sulphamoyloxy, alkylsulphamoyloxy, alkylsulphonyloxy or sulpho, sulphony, carboxamido, N-monoalkylcarboxamido, N,N-dialkylcarboxamido or carboxy, where the substituents, independently of one another, occur once or several times and their alkyl moiety contains 1 to 6 carbon atoms, and where the heterocyclic moiety is monocyclic or bicyclic and contains 3 to 10 ring atoms, of which one or more are selected from the series comprising: oxygen, sulphur and nitrogen.

A preferred class of compounds I is that, in which R¹ denotes hydrogen, hydroxymethyl or 1-hydroxyethyl, R² denotes hydrogen or methyl and R³ denotes substituted or unsubstituted alkoxy, heterocyclyloxy, acyloxy, carbamoyloxy, N-heterocyclyl, acylamino, carbamoylamino, imidoylamino where the foregoing alkyl,

acyl, thioacyl, or imidoyl molecule parts contain 1 to 3 carbon atoms and the heterocyclyl moiety is monocyclic and contains 3 to 6 ring atoms, of which one or more are selected from the series comprising : oxygen, sulphur and nitrogen and where the substituents of the above-mentioned groups R^3 may be: alkyl, acyl, thioacyl, heterocyclyl, hydroxyl, hydroxyalkyl, alkoxy, hydroxyalkoxy, aminoalkoxy, amidinoalkoxy, guanidinoalkoxy, acyloxy, heterocycliloxy, alkylheterocycliloxy, hydroxyalkylheterocycliloxy, aminoalkylheterocycliloxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, carbamoyloxy, alkylcarbamoyloxy, dialkylcarbamoyloxy, thiocarbamoyl, alkylthiocarbamoyl, dialkylthiocarbamoyl thiocarbamoyloxy, alkylthiocarbamoyloxy, dialkylthiocarbamoyloxy, mercapto, alkylthio, hydroxyalkylthio, aminoalkylthio, monoalkylaminoalkylthio, dialkylaminoalkylthio, amidinoalkylthio, acylthio, heterocyclylthio, alkylheterocyclylthio, hydroxyalkylheterocyclylthio, aminoalkylheterocyclylthio, carbamoylthio, monoalkylcarbamoylthio, dialkylcarbamoylthio, thiocarbamoylthio, alkylthiocarbamoylthio, dialkylcarbamoylthio, amino, monoalkylamino, hydroxyalkylamino, aminoalkylamino, dialkylamino, oxo, oximino, or alkylimino, imidoylamino, alkylimidoylamino, dialkylimidoylamino, tetraalkylammonium, cycloalkylamino, heterocyclylamino, alkylheterocyclylamino, heterocyclylcarbonylamino, alkylheterocyclylcarbonylamino, acylamino, amidino, monoalkylamidino, dialkylamidino, guanidino, alkylguanidino, dialkylguanidino, carbamoylamino, thiocarbamoylamino, alkylcarbamoylamino, thiocarbamoylamino, alkylthiocarbamoylamino, nitro, chlorine, bromine, fluorine, iodine, azido, cyano, alkylsulphinyl, alkylsulphonyl, sulphonamido, sulphamoyloxy, alkylsulphamoyloxy, alkylsulphonyloxy or sulpho, sulphoxy, carboxamido, N-monoalkylcarboxamido, N,N-dialkylcarboxamido or carboxy, where the substituents, independently of one another, occur once or several times and their alkyl moiety contains 1 to 6 carbon atoms, and where the heterocyclic moiety is monocyclic and contains 3 to 6 ring atoms, of which one or more are selected from the series comprising: oxygen, sulphur and nitrogen.

An especially preferred class of compounds I, according to the invention, is the one, in which R^1 denotes 1-hydroxyethyl, R^2 denotes methyl and R^3 denotes substituted alkoxy, acylamino, alkylcarbamoylamino, alkoxycarbamoylamino, N-heterocyclyl and imidoylamino, where the foregoing alkyl, acyl or imidoyl molecule parts contain 1 to 3 carbon atoms and the heterocyclyl moiety is monocyclic and contains 3 to 6 ring atoms, of which one or more are selected from the series comprising: oxygen, sulphur and nitrogen and where the substituents of the above-mentioned groups R^3 are basic

groups such as amino, alkylamino, dialkylamino, imidoyl, amidino and guanidino. In this case the compounds I according to the invention are very polar and can exist in their zwitterionic form. Therefore such compounds are especially active against Gram-negative bacteria including *Pseudomonas aeruginosa*.

5

A selection of compounds I according to the invention showed high antibacterial activity in the disc susceptibility test after application of 10 micrograms with the following inhibition diameters: *Staph. aureus* (9 - 39 mm), *E. coli* (27 - 34 mm), *E. cloacae* (23 - 27 mm) and *Ps. aeruginosa* (13 - 26 mm). These data correspond to those of a clinically useful injectable carbapenem as described in *Journ. Antimicrob. Chemotherapy* **24**, (1989), Suppl. A, 253.

10

Therefore these new antibiotics are active against a range of bacterial pathogens, which representatively include both gram-positive and gram-negative bacteria such as *Staphylococcus aureus*, *Escherichia coli*, *Enterobacter cloacae*, *Enterococcus* and *Pseudomonas aeruginosa*.

15

Surprisingly, we found that the compounds according to the invention strongly inhibited bacterial β -lactamases isolated from *Enterobacter cloacae* and *Escherichia coli*. Moreover, all tested ceftazidime resistant Gram-negative pathogens became susceptible to a combination of ceftazidime and the compounds according to the invention. Thus, these compounds are also very potent β -lactamase inhibitors. The very high activity as β -lactamase inhibitors of the compounds I according to the invention was also observed with isolated bacterial enzymes in the nitrocefin test (R. Reimer, *Methodicum Chemicum: Antibiotics, Vitamins and Hormons*; F. Korte, M. Goto, eds., Thieme, Stuttgart, 1977, p.11, E. Wasielewski, *Arzneimittel*, Vol. 4; *Chemotherapeutica*, Part 1, Verlag Chemie, Weinheim 1972).

20

25

A representative of the compounds I according to the invention showed high blood levels in mice after oral treatment with 25mg per kg, showing the oral absorbability.

30

Therefore the present invention has the objective of providing a new class of carbapenem antibiotics and β -lactamase inhibitors, which is important in veterinary and human therapy and in inanimate systems. The high and broad spectrum antibacterial activity and β -lactamase inhibition potency of the compounds according

35

to the invention, in combination with their oral activity, could not be expected to this extent from the prior art.

5 The new compounds according to the invention are valuable antimicrobial substances which are active against most Gram-positive and Gram-negative pathogens including also most penicillin- and cephalosporin resistant and anaerobic bacteria.

The free acid and in particular the alkaline and earth metal salts or the zwitterionic species are useful bactericides and can be employed to remove pathogens from dental and medical equipment for removing microorganisms and for therapeutic use in
10 humans and animals. For this latter purpose, pharmaceutically acceptable salts as are known per se and are used in the administration of penicillins and cephalosporins, are used. These salts can be used together with pharmaceutically acceptable liquid and solid excipients to form suitable dose unit forms such as pills, tablets, capsules, suppositories, syrups, elixirs and the like, which can be prepared by processes which
15 are known per se.

The new compounds are valuable antibiotics against most pathogenic bacteria and, accordingly, are used in human and veterinary medicine. They can be used as antibacterial medicaments for treating infections caused by Gram-positive and Gram-
20 negative bacteria, for example by *Staphylococcus aureus*, *Escherichia coli*, *Klebsiella pneumoniae*, *Bacillus subtilis*, *Salmonella typhosa*, *Enterobacter cloacae*, *Enterococcus*, *Pseudomonas aeruginosa* and *Bacterium proteus*.

The antibacterial agents can furthermore be used as additives for animal feeds, for
25 preserving foodstuffs or feeds and as disinfectants. For example, they can be used in aqueous preparations in concentrations in the range 0.1 to 100 parts of antibiotic/million parts of solution for destroying and inhibiting the growth of harmful bacteria on medical equipment and as bactericides in industrial applications, for example in water-based paints and in soft water for paper mills, for inhibiting the
30 growth of harmful bacteria.

The products according to the invention may be used alone or together with other active components in any of a large number of pharmaceutical preparations. These preparations can be used in capsule form or as tablets, powders or liquid solutions or

as suspensions or elixirs. They can be administered orally, intravenously or intramuscularly.

The preparations are preferably administered in a form which is suitable for absorption through the gastrointestinal tract. Tablets and capsules for oral administration may be in dose unit form and can contain customary medicament excipients, such as binders, for example syrup, gum arabic, gelatin, sorbitol or polyvinylpyrrolidone, fillers, for example lactose, sugar, maize starch, calcium phosphate, sorbitol or glycine, lubricants, for example magnesium stearate, talc, polyethylene glycol or silica, disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulfate. The tablets may be coated by processes which are known per se. Oral liquid preparations can be in the form of aqueous or oily suspensions, solutions, emulsions, syrups, elixirs and the like or can exist as dry product, for example for reconstitution before using water or other suitable excipients. Liquid preparations of this type can contain additives which are known per se, such as suspending agents, for example sorbitol syrup, methylcellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel, or hydrogenated edible oils, for example almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol, preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid. Suppositories contain suppository bases which are known per se, for example cocoa butter or other glycerides.

The preparations for injection can be in dose unit form in ampoules or in containers containing several doses along with an added preservative. The preparations can be in the form of suspensions, solutions or emulsions in oily or aqueous excipients, and they may contain formulation agents such as suspending agents, stabilizers and/or dispersants. Alternatively, the active component may be in powder form for reconstitution before using a suitable excipient, for example sterile, pyrogen-free water.

The preparations can also be in suitable form for absorption through the mucous membranes of the nose and of the throat or of the bronchial tissue, and can be in the form of powders or liquid sprays or inhalants, sucking sweets, as throat paints, etc. For eye and ear medications, the preparations can be used in the form of individual capsules in liquid or semi-solid form or they can be used as drops, etc. Topical

applications can exist or be formulated in hydrophobic vehicles as ointments, creams, lotions, paints, powders, etc.

5 The preparations according to the invention can contain, in addition to the excipient, other components such as stabilizers, binders, antioxidants, preservatives, lubricants, suspending agents, viscosity control agents or flavours or the like.

10 The preparations according to the invention may also contain, in addition to the excipient, enzyme inhibitors, e.g. cilastatin (Merck Index, 11th ed. 2275) to increase the therapeutic effect.

15 In addition, the preparations may contain one or more active antibacterial components to obtain a broader antibiotic range. Examples for such other active components are antibiotics, preferably β -lactam antibiotics, e.g. penicillins such as Ampicillin or Amoxycillin or cephalosporins such as Cephalexin, Cefachlor or Ceftazidime. With such added conventional β -lactam antibiotics, the active component according to the invention, acts as an antibacterial and as an inhibitor of bacterial β -lactamases.

20 For veterinary medicine, the preparations can be formulated, for example, as an intramammary preparation in either long-acting or rapid-release vehicles.

The dose to be administered is highly dependent on the state of the subject to be treated and the weight of the host, and on the method and frequency of administration. In general, a daily oral dose contains about 10 to about 200 mg of active component/kg of body weight of the subject in case of one or more
25 administrations per day. A preferred daily dose for adult humans is in the range of about 20 to 120 mg of active component/kg of body weight.

The preparations according to the invention can be administered in various unit dose forms, for example in solid or liquid dose forms which can be taken orally. The
30 preparations can contain 0.1 to 99 % of active material per unit dose, either in solid or in liquid form. The preferred range is about 10 to 60 %. The preparations generally contain 15 to about 1500 mg of active component but it is generally preferred to use a dose amount in the range about 250 to 1000 mg. In the case of parenteral administration, the unit dose is normally the pure compound in a sterile water solution
35 or in the form of a soluble powder, which may be dissolved.

The examples below illustrate the products, processes, preparations and methods of treatment according to the invention.

5 Example 1

Methoxymethanethiol

To a 5.2 N aqueous solution of sodium hydroxide (7.7 ml, 40 mmol) ,at 0° C, with
10 stirring, methoxymethyl thiolacetate (2.40 g, 20 mmol) was added. After 30 min, to the
resulting yellow solution 5 N aqueous hydrogen chloride (4.0 ml, 20 mmol) was added,
where upon an oily layer separated. After saturation of the aqueous layer with sodium
chloride at 0 °C, the oily phase was separated, dried with magnesium sulfate, filtered
and the filtrate distilled at ambient pressure, yielding a colourless liquid, b.p. 51°C.
15 NMR-spectrum in CDCl₃ 2.0 (t, 1H, J = 12 Hz), 3.4 (s, 3H), 4.8 (d, 2H, J = 12 Hz) ppm.

Alternatively, the two phase mixture was extracted with deuteriochloroform. The
resulting solution was dried over magnesium sulfate, filtered and stored in a
refrigerator. It contained pure title compound (1.17 g, 80 %).

20 This solution was extracted with 2 N aqueous sodium hydroxide (7.5 ml, 15 mmol)
and the extract immediately lyophilized in high vacuo yielding colourless solid sodium
methoxymethylthiolate.

Example 2

25

2-(Azidoethyloxy)methanethiol

Into a mixture of 2-azidoethanol (2.0 g, 23 mmol) and trioxane (0.74 g, 8.2 mmol) dry
hydrogen chloride was introduced at -10 °C. After 1.5 hr, the solid liquidified. After
30 flushing of the apparatus with nitrogen the mixture consisted of (2-azidoethyl)
chloromethyl ether. NMR-spectrum in CDCl₃: 3.5 (m, 2H), 3.9 (m, 2H), 5.5 (s, 2H)
ppm.

The (2-azidoethyl) chloromethyl ether (crude product, 23 mmol) was added at 0 °C to
35 a stirred suspension of potassium thiolacetate (2.63 g, 23 mmol) in dry ether (7.5 ml).

The mixture was allowed to stir at room temperature overnight. Insoluble material was removed by filtration and the filtrate was evaporated in vacuo, leaving an orange liquid. It was distilled in high vacuum (0.002 mm) using a short path distillation apparatus and a safety shield. Pure (2-azidoethoxy)methyl thiolacetate, b.p. 80 - 90 °C/0.002 mm was obtained as a pale yellow liquid in 65 % yield. NMR-spectrum in CDCl₃: 2.38 (s, 3H), 3.36 (m, 2H), 3.61 (m, 2H), 5.10 (s, 2H) ppm.

To 0.20 N aqueous NaOH (121 ml, 24.2 mmol) at 0 °C a solution of (2-azidoethoxy)methyl thiolacetate (848 mg, 4.84 mmol) in tetrahydrofuran (5 ml) was added dropwise with stirring. The reaction mixture was allowed to stir for 15 min at 0 °C. The resulting solution was washed with ether (100 ml) and then acidified at 0 °C with 1.0 N aqueous HCl (19.4 ml) to a pH of 6. The aqueous solution was then extracted twice with portions of ether (50 ml). The combined ether layers were dried over magnesium sulfate and solvent removed in vacuo (13 mm). The resulting crude product was chromatographed on silica gel (200 - 63 µm, 23 g) using hexane-ether (9 : 1) to give colourless title compound in 47 % yield after drying at 13 mm. NMR-spectrum in CDCl₃: 2.0 (t, 2H, = 10 Hz), 3.4 (t, 2H, J = 6 Hz), 3.7 (t, 2H, J = 6 Hz), 4.8 (d, 2H, J = 10 Hz) ppm.

20

Example 3

(2-Azido-1,1-dimethylethoxy)methanethiol

To a stirred suspension of sodium hydride (310 mg, 13 mmol) in dry tetrahydrofuran (5ml), at 0 °C, a solution of 1-azido-2-methyl-2-propanol (1.15 g, 10 mmol) in dry THF (2 ml) was added. When hydrogen evolution had stopped, to the pale yellow solution dry hexamethylphosphorous triamide (3 ml) and chloromethyl methyl ether (1.14 ml, 15 mmol) were added at 0° C and the reaction mixture stirred at room temperature overnight. The reaction mixture was poured on 10% aqueous NaCl solution (40 ml) and extracted twice with two portions (150 and 50 ml) of ether. The combined ether layers were washed twice with 10% NaCl (50 ml) and with saturated NaCl (50 ml). The ether layer was dried over magnesium sulfate and the solvent removed in vacuo (13 mm) yielding formaldehyde ((2-azido-1,1-dimethylethyl) methyl acetal (1.41 g 89%). NMR-spectrum in CDCl₃: 1.28 (s, 6H), 3.22 (s, 2H), 3.39 (s, 3H), 4.74 (s, 2H) ppm.

To a stirred solution of formaldehyde ((2-azido-1,1-dimethylethyl) methyl acetal (1.35 g, 8.47 mmol) in dry methylene chloride (5 ml) 1M boron trichloride solution (3.64 ml, 3.64 mmol) was added at 0 °C. The reaction mixture was stirred at room temperature for 3 hr to give a solution of (2-azido-1,1-dimethylethyl) chloromethyl ether. NMR-spectrum in CDCl₃: 1.36 (s, 6H), 3.24 (ABq, 2H), 5.60 (s, 2H) ppm.

To a suspension of powdered solid potassium thioacetate (1.28 g, 11.3 mmol) in dry methylene chloride (8 ml), at 0 °C, the above-mentioned solution (8.0 ml) containing (2-azido-1,1-dimethylethyl) chloromethyl ether (1.23 g, 7.53), was added with stirring and the resulting suspension allowed to stir at room temperature overnight. The resulting mixture was diluted with methylene chloride (80 ml), washed three times with portions (30 ml each) of water and once with saturated NaCl (30 ml). The organic layer was dried over magnesium sulfate and the solvent removed in vacuo (13 mm) to give crude (2-azido-1,1-dimethylethoxy)methyl thiolacetate (1.30 g, 85 %). It was purified by column chromatography on silica gel (40 - 60 µm) using hexane-ether (4 : 1) yielding pure (2-azido-1,1-dimethylethoxy)methyl thiolacetate (0.81 g, 53 %) as a colourless liquid. NMR-spectrum in CDCl₃: 1.28 (s, 6H), 2.37 (s, 3H), 3.21 (s, 2H), 5.02 (s, 2H).

To a stirred 0.1N solution of sodium hydroxide (25 ml, 2.5 mmol), at 0 °C, (2-azido-1,1-dimethylethoxy)methyl thiolacetate (102 mg, 0.5 mmol), dissolved in THF (0.5 ml) was added. The reaction mixture was stirred at 0 °C for 90 min. The solution was washed with ether (15 ml) and then acidified at 0 °C with 1N HCl (1.8 ml, 1.8 mmol) to pH 6 - 7. The solution was stirred at 0 °C for 30 min and then transferred to a separatory funnel. After having shaken for 3 min, the organic layer was collected and the aqueous layer reextracted twice with portions (8 ml) of ether. The combined ether layers were dried over magnesium sulfate and the solvent removed in vacuo (13 mm) yielding the title compound as a pale yellow liquid (67 mg, 83 %). NMR-spectrum in CDCl₃: 1.28 (s, 6H), 2.18 (t, 1H, J = 10 Hz), 3.23 (s, 2H), 4.73 (d, 2H, J = 10 Hz) ppm.

Example 4

N-(Mercaptomethyl)-acetamide

N-(Hydroxymethyl)-acetamide (13.4 g, 0.15 mol) and thiolacetic acid (14.3 g, 0.188 mol) were heated for 3 days at 40 °C. The resulting mixture was chromatographed on

silica gel (63 - 200 μ m, 700 g) with toluene-ethyl acetate 4 : 1 and 1 : 1 to give pure crystalline acetamidomethyl thiolacetate (14.2 g, 64 %), m.p. 93 - 94 °C.

Acetamidomethyl thiolacetate (1.47 g, 10 mmol) was dissolved in 2.0 N hydrogen chloride in dry methanol (1.8 ml) and the resulting solution kept at room temperature for 3.5 hr. It was neutralized (pH = 7) with a 2 N solution of sodium methoxide in dry methanol (1.8 ml). Precipitated sodium chloride was removed by filtration and the filtrate evaporated in vacuo. The residue was chromatographed on silica gel (63 - 200 μ m, 30 g) using ethyl acetate to give the pure title compound (0.70 g, 67 %). It was kept at -30 °C under argon. NMR-spectrum in $CDCl_3$: 1.95 (s, 3H), 2.38 (t, 1H, J = 9 Hz), 4.28 (dd, 2H, J = 9 Hz) 6.81 (broad s, 1H) ppm.

Example 5

15

2-Azido-N-(mercaptomethyl)-acetamide

A mixture of 2-azido-acetamide (1.40 g, 14 mmol), 30 % aqueous (methanol free) formaldehyde (1.40 g, 14 mmol) and 1.0 N aqueous KOH (0.28 ml, 0.28 mmol) was stirred at 0 °C for 4 hrs. To the reaction mixture 1.0 N aqueous HCl was added (pH = 7) and the resulting mixture evaporated in vacuo. The residue was suspended in ethyl acetate (50 ml), the solution dried over magnesium sulfate, filtered and the filtrate concentrated to a volume of 5 ml. Chromatography on silica gel (63 - 200 μ m, 18 g) with ethyl acetate afforded 2-azido-N-(hydroxymethyl)-acetamide as a colourless oil in 90 % yield. NMR-spectrum in $CDCl_3$: 3.6 (broad signal, 1H), 4.0 (s, 2H), 4.8 (d, 2H, J = 6 Hz), 7.3 (broad signal 1H) ppm.

To 2-azido-N-(hydroxymethyl)-acetamide (650 mg, 5 mmol) at -10 °C oxalyl chloride (635 mg, 5 mmol) was added. After 10 min gas evolution had ceased. The mixture was diluted in $CDCl_3$. NMR-Spectrum in $CDCl_3$: 4.1 (s, 2H), 5.2 (d, 2H, J = 10 Hz), 7.3 (broad signal, 1H) ppm. The NMR was consistent with 2-azido-N-(chloromethyl)-acetamide (yield 75 %).

To the solution of the crude 2-azido-N-(chloromethyl)-acetamide (715 mg) in $CDCl_3$ (4 ml) potassium thioacetate (520 mg, 4.6 mmol) was added at 0 °C and the suspension

stirred at room temperature overnight. The mixture was diluted with chloroform (50 ml) and the solution subsequently washed twice with portions (15 ml) of water and with brine (10 ml). The organic layer was dried over magnesium sulfate and the solvent evaporated in vacuo leaving a noncrystalline solid (530 mg). It was chromatographed on silica gel (63 - 200 μ m) using toluene-ethyl acetate (2 : 1) to give 400 mg (56 %) of pure (2-azidoacetamido)methyl thiolacetate. NMR spectrum in CDCl_3 : 2.4 (s, 3H), 4.0 (s, 2H), 4.7 (d, 2H, $J = 7$ Hz), 7.2 (broad signal, 1H) ppm.

Pure (2-azidoacetamido)methyl thiolacetate (56 mg, 0.28 mmol) was dissolved in 1.8 N HCl in dry methanol (0.6 ml, 1.1 mmol) and the solution stirred at room temperature for 6 hrs. It was neutralized with 2.2 N sodium methoxide in dry methanol (0.46 ml, 1.03 mmol) (pH = 6). The precipitated sodium chloride was removed by filtration and the filtrate diluted with DMF-d_6 (0.7 ml) and then methanol was removed in vacuo (15 mm) and finally in high vacuo (0.001 mm).

The DMF-d_6 solution was kept at -80°C . NMR spectroscopy showed the title compound (yield 56 %, determined with 10 μ l of benzene as internal standard). NMR spectrum in DMF-d_6 : 2.9 (broad signal, 1H), 3.95 (s, 2H), 4.38 (dd, 2H), 8.9 (broad signal, 1H) ppm.

Example 6

1-Ethyl-4-(mercaptomethyl)-piperazine-2,3-dione

To a solution of 1-ethylpiperazine-2,3-dione (2.13 g, 15 mmol) in 30 % aqueous (methanol free) formaldehyde (15 mmol) potassium hydroxide (150 mg, 2.7 mmol) was added and the mixture stirred at 50°C for 7 days. It was neutralized with 5 N aqueous hydrochloric acid (50 μ l) to pH = 7. The mixture was evaporated at 15 mm and then dried in high vacuo (0.001 mm) to give 1-ethyl-4-(hydroxymethyl)-piperazine-2,3-dione as a colourless solid (100 %). NMR-spectrum in CDCl_3 : 1.15 (broad signal, 1H), 1.15 (t, 3H, $J = 7$ Hz), 3.47 (q, 2H, $J = 7$ Hz), 3.54 (m, 2H), 3.68 (m, 2H), 4.88 (s, 2H) ppm.

To 1-ethyl-4-(hydroxymethyl)-piperazine-2,3-dione (156 mg, 0.906 mmol) oxalyl chloride (78 μ l, 0.906 mmol) was added at -10°C . The mixture was stirred at -10°C

for 2 hrs. Gas evolution had ceased after 30 min. The reaction mixture was dried in high vacuo to give 1-(chloromethyl)-4-ethyl-piperazine-2,3-dione (100 %). NMR-spectrum in CDCl_3 : 1.15 (t, 3H, $J = 7$ Hz), 3.42 (q, 2H, $J = 7$ Hz), 3.65 (broad signal, 4H), 5.30 (s, 2H) ppm.

5

To a solution of crude 1-(chloromethyl)-4-ethyl-piperazine-2,3-dione (170 mg, 0.9 mmol) in CDCl_3 (1 ml) solid potassium thioacetate (123 mg, 1.08 mmol) was added with stirring at 0 °C. The reaction mixture was allowed to stir at room temperature overnight. The mixture was centrifuged and the supernatant solution collected. The residual solid (KCl) was washed with CDCl_3 (2 ml) and the organic solutions combined and the solvent removed in vacuo. The residue was chromatographed on silica gel (6g, 63 - 200 μm) using chloroform-methanol (19 : 1) to give 1-(acetylthiomethyl)-4-ethyl-piperazine-2,3-dione as a white solid (overall yield 44 %). NMR-spectrum in CDCl_3 : 1.22 (t, 3H, $J = 7$ Hz), 2.44 (s, 3H), 3.48 (q, 2H, $J = 7$ Hz), 3.4 - 3.7 (m, 4H), 4.95 (s, 2H) ppm.


1-(Acetylthiomethyl)-4-ethyl-piperazine-2,4-dione (74 mg, 0.32 mmol) was dissolved in 1.95 N HCl in methanol (0.56 ml, 1.2 mmol) and the solution allowed to stir at room temperature for 6 hrs. The mixture was neutralized at 0 °C with 2.24 N sodium methoxide in dry methanol (0.54 ml, 1.2 mmol) to pH = 6. Precipitated sodium chloride was removed by filtration and the filtrate evaporated in vacuo and the residue dried at 0.001 mm. It was chromatographed on silica gel (2.0 g, 63 - 200 μm) using chloroform-methanol (19 : 1) to give the title compound as a colourless solid (yield 80 %). NMR-spectrum in CDCl_3 : 1.23 (t, 3H, $J = 7\text{Hz}$), 2.43 (broad signal, 1H) 3.55 (q, 2H, $J = 7\text{Hz}$), 3.67 (broad s, 4H), 4.60 (broad s, 2H) ppm.

25

Example 7


Sodium or potassium (4R,5S,6S)-6-((1'R)-hydroxyethyl)-3-(methoxymethylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (Ia)

30



35

p-Nitrobenzyl (4R,5S,6S)-6-((1'R)-hydroxyethyl)-3-(methoxymethylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate



To a solution of p-nitrobenzyl (4R,5R,6S)-3-(diphenyloxyphosphinyloxy)-6-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (892 mg, 1.5 mmol) in dry dimethyl formamide (15 ml), at -50 °C, a solution of methoxymethanethiol (152 mg, 1.95 mmol) in CDCl₃ (3 ml) and subsequently diisopropylethylamine (334 µl, 1.95 mmol) was added. The reaction mixture was allowed to reach 0 °C. After 2 hr at 0 °C, the reaction mixture was diluted with ethyl acetate (300 ml) and the solution left at room temperature for 5 min.

20

This solution was washed subsequently with 10 % aqueous K₂CO₃ solution (125 ml), three portions of water (100 ml each) and with brine (100 ml). The organic layer was dried over magnesium sulfate and the solvent removed in vacuo. The residue was chromatographed on silica gel (50g, 63 - 200 µm) using toluene ethyl acetate (2 : 1) and (1 : 1) to give the title compound as a pale yellow non-crystalline solid (yield 78 %). IR spectrum in CH₂Cl₂: 3600, 3050, 2900, 1770, 1710, 1605, 1520, 1345, 1210, 1135, 1080 cm⁻¹.

25

Potassium (4R,5S,6S)-6-((1'R)-hydroxyethyl)-3-(methoxymethylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

30


To 10 % palladium on carbon (750 mg), prehydrogenated at 0 °C in a two phase mixture of ethyl acetate (30 ml) and KHCO₃ (85 mg, 0.85 mmol) in water (12 ml) a solution of p-nitrobenzyl (4R,5S,6S)-6-((1'R)-hydroxyethyl)-3-(methoxymethylthio)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (479 mg, 1.13 mmol) in

35

ethyl acetate (10 ml) was added by a syringe. The mixture was then hydrogenated at ambient pressure and 0 °C. After 70 min, the uptake of hydrogen (70 ml) became very slow. Additional catalyst (150 mg) was added and hydrogenation was continued for additional 100 min. Additional hydrogen (50 ml) was consumed. The catalyst was removed by filtration, washed with ethyl acetate (5ml) and water (2 ml) and the filtrate transferred to a separatory funnel. The aqueous layer was collected and the organic layer extracted with a solution of KHCO_3 (28 mg, 0.28 mmol) in water (3 ml). The combined aqueous solutions were evacuated in order to remove residual ethyl acetate and then lyophilized at -30 °C in high vacuo (0.001 mm) to give the pure title compound as white powder (yield 50 %). UV-spectrum in water $\lambda_{\text{max}} = 292 \text{ nm}$ ($\epsilon = 8000$). NMR spectrum in D_2O (int. standard $\text{Me}_3\text{SiCD}_2\text{CD}_2\text{COONa}$): 1.21 (d, 3H, $J = 7 \text{ Hz}$), 1.31 (d, 3H, $J = 6 \text{ Hz}$), 3.43 (s, 3H), 3.45 (m, 1H), 3.52 (m, 1H), 4.2 - 4.3 (m, 2H), 4.76 and 5.03 (ABq, $J = 8 \text{ Hz}$, S- $\text{CH}_2\text{-O}$) ppm.


Example 8

(4R,5S,6S)-3-((2-Aminoethoxy)methylthio)-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (Ib)



p-Nitrobenzyl (4R,5S,6S)-3-((2-azidoethoxy)methylthio)-6-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

According to the procedure described in Example 7, using (2-azidoethoxy)methanethiol, the title p-nitrobenzyl ester was prepared in 80 % yield as a pale yellow non-crystalline solid after chromatography with toluene-ethyl acetate (1 : 1). IR spectrum in CH_2Cl_2 : 3600, 3050, 2900, 2100 (N_3), 1770, 1710, 1610, 1520, 1350, 1210, 1140, 1085 cm^{-1} .




15 (4R,5S,6S)-3-((2-Aminoethoxy)methylthio)-6-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (zwitterionic form)

10 % Palladium on carbon (700 mg) was prehydrogenated at 0 °C in a two phase mixture of ethyl acetate (30 ml) and water (15 ml) and a solution of p-nitrobenzyl (4R,5S,6S)-3-((2-azidoethoxy)methylthio)-6-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (422 mg, 0.884 mmol) in ethyl acetate (10 ml) was added by a syringe at 0 °C. After 65 min of hydrogenolysis at 0 °C and ambient pressure, the uptake of hydrogen (70 ml) became slow. Additional catalyst (100 mg) was added and hydrogenation continued at 0 °C for additional 75 min. Additional hydrogen (35 ml) was absorbed. The catalyst was removed by filtration, washed with ethyl acetate (5 ml) and water (3 ml) and the filtrate transferred to a separatory funnel. The aqueous layer was collected and the organic layer extracted with cold water (3 ml). The combined aqueous solutions were evacuated in order to remove residual ethyl acetate and then lyophilized at -30 °C in high vacuo (0.001 mm) to give the title compound as a white powder in 68 % yield. UV-spectrum in water:

30 λ_{max} 292 nm ($\epsilon = 8000$). NMR spectrum in D₂O (internal standard Me₃SiCD₂CD₂COONa): 1.21 (d, 3H, J = 7 Hz), 1.30 (d, 3H, J = 6 Hz), 3.23 (m, 2H), 3.48 (dd, 1H), 3.55 (m, 1H) 3.70 and 3.93 (2m, 2H), 4.26 (complex signal, 2H), 4.78 and 5.17 (ABq, 2H, J = 11 Hz, S-CH₂-O) ppm.

Example 9

(4R,5S,6S)-3-((2-(Formimidoylamino)ethoxy)methylthio)-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (Ic) (zwitterionic form)




To a solution of (4R,5S,6S)-3-((2-aminoethoxy)methylthio)-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (4.7 mg, 13.8 μmol) in water (0.18 ml) at 0 °C a 0.5 N solution of KHCO_3 (83 μl , 41 μmol) and subsequently solid ethyl formimidate hydrochloride (4.5 mg, 41 μmol) was added. After 30 min at 0 °C, additional 0.5 N KHCO_3 (55 μl , 28 μmol) and ethyl formimidate hydrochloride (3.0 mg, 28 μmol) were added (pH = 8) and the reaction mixture stirred at 0 °C for 60 min. Finally, a 0.5 M solution of potassium carbonate (9 μl , 45 μmol) was added and the mixture stirred for 30 min at 0 °C.

The solution was purified at 0 °C by passing slowly through a ion exchange column containing Dowex 50W x 4 (0.5g, Na^+ -cycle) using water as an eluent. 12 Fractions (0.5 ml) were taken and investigated by TLC (reversed phase silica gel RP-18, water-acetonitrile (3 : 1). The product containing fractions were combined and the acetonitrile removed by evaporation in high vacuum. The resulting aqueous solution was lyophilized at 0.001 mm to give the title compound in 31% yield as a colourless amorphous solid. UV spectrum in water:

λ_{max} = 292 nm (ϵ = 8000). NMR spectrum in D_2O (internal standard


$\text{Me}_3\text{SiCD}_2\text{CD}_2\text{COONa}$): 1.21 (d, 3H, J = 7 Hz), 1.30 (d, 3H, J = 6 Hz), 3.4 - 4.0 (m,

6H), 4.2 - 4.3 (m, 2H), 4.71 and 5.17 (ABq, 2H, J = 7 Hz), 7.8 (d, 1H, J = 3 Hz).



10 Example 10


(4R,5S,6S)-3-((2-Amino-1,1-dimethylethoxy)methylthio)-6-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (Id)



20 p-Nitrobenzyl (4R,5S,6S)-3-((2-azido-1,1-dimethylethoxy)methylthio)-6-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylate

According to the procedure described in Example 7, using (2-azido-1,1-dimethylethoxy)methanethiol, the title p-nitrobenzyl ester was prepared in 72 % yield as a pale yellow non-crystalline solid after chromatography with toluene-ethyl acetate (2 : 1). IR spectrum in CH₂Cl₂: 3600, 3025, 2990, 2105 (N₃), 1775, 1710, 1610, 1525, 1350, 1210, 1135, 1055 cm⁻¹.

25




(4R,5S,6S)-3-((2-amino-1,1-dimethylethoxy)methylthio)-6-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (zwitterionic form)

According to the procedure described in Example 8, the title compound was prepared in 28 % yield as a colourless lyophilized powder by hydrogenolysis of p-nitrobenzyl (4R,5S,6S)-3-((2-azido-1,1-dimethyl-ethoxy)methylthio)-6-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylate. UV spectrum in H₂O: λ_{max} = 292 nm (ϵ = 8000).


Example 11

Sodium or potassium (4R,5S,6S)-3-(acetamidomethylthio)-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (Ie)



p-Nitrobenzyl (4R,5S,6S)-3-(acetamidomethylthio)-6-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

According to the procedure described in Example 7, using N-(mercaptomethyl)-acetamide, the title p-nitrobenzyl ester was prepared in 36 % yield as a pale yellow non-crystalline solid after chromatography with ethyl acetate. IR spectrum in CH₂Cl₂: 3600 (OH), 3430 (NH), 3050, 2950, 1770 (β-lact C=O), 1705 (ester C=O) 1675 (amide I), 1605, 1525 (NO₂), 1505 (amide II), 1350(NO₂), 1210, 1135 cm⁻¹.




Potassium (4R,5S,6S)-3-(acetamidomethylthio)-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

According to the procedure described in Example 7 the p-nitrobenzyl ester was hydrogenolyzed to give the title compound as a white powder in 54 % yield after lyophilisation. UV-spectrum in water: λ_{max} 294 nm (ε = 8000). NMR-spectrum in D₂O (internal standard Me₃CD₂CD₂COONa): 1.31 (d, 3H, J = 7 Hz), 1.30 (d, 3H, J = 6 Hz), 2.01 (s, 3H), 3.42 - 3.48 (2m, 2H), 4.20 - 4.25 (2m, 2H), 4.36 and 4.66 (ABq, 2H, J = 14 Hz, S-CH₂-N) ppm.


Example 12

(4R,5S,6S)-3-((2-Aminoacetamido)methylthio)-6-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (If)



p-Nitrobenzyl (4R,5S,6S)-3-((2-azidoacetamido)methylthio)-6-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

- 15 According to the procedure described in Example 7, using 2-azido-N-(mercaptomethyl)-acetamide the title p-nitrobenzyl ester was prepared as a pale yellow non-crystalline solid after chromatography with toluene-ethyl acetate (1 : 1) and ethyl acetate in 63 % yield. IR-spectrum in CH_2Cl_2 : 3600 (OH), 2900 (NH), 2100 (N_3), 1770 (β -lactam $\text{C}=\text{O}$), 1705 and 1695 (ester and amide I), 1600 ($\text{C}=\text{C}$), 1520 (NO_2 and amide II), 1350 NO_2 , 1205, 1130 cm^{-1} .




(4R,5S,6S)-3-((2-Aminoacetamido)methylthio)-6-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (zwitterionic form)

According to the procedure described in Example 8 the p-nitrobenzyl ester was
 5 hydrogenolyzed to give the title compound as a white powder in 53 % yield after
 lyophilisation. UV-spectrum in water: λ_{max} 292 nm ($\epsilon = 8000$). NMR spectrum in D₂O
 (internal standard Me₃CD₂CD₂COONa): 1.21 (d, 3H, J = 7 Hz), 1.30 (d, 3H, J = 6 Hz),
 3.5 (complex signal, 2H), 3.77 (s, 2H), 4.25 (complex signal, 2H), 4.41 and 4.72 (ABq,
 2H, J = 14 Hz, S-CH₂-N) ppm.

10

Example 13

Sodium or potassium (4R,5S,6S)-3-((2,3-dioxo-4-ethyl-piperazinyl)methylthio)-6-((1'R)-
 15 hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (lg)




20

p-Nitrobenzyl (4R,5S,6S)-3-((2,3-dioxo-4-ethyl-piperazinyl)methylthio)-6-((1'R)-
 hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

25 To a solution of p-nitrobenzyl (4R,5R,6S)-3-(diphenyloxyphosphinoyloxy)-6-((1'R)-
 hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate (118 mg,
 0.2 mmol) in dry dimethyl formamide (1.5 ml), at -50 °C, a solution of 1-ethyl-4-
 (mercaptomethyl)-piperazine-2,3-dione (49 mg, 0.26 mmol) in CDCl₃ (1.2 ml) and
 subsequently diisopropylethylamine (44 μ l, 0.26 mmol) were added. The reaction
 30 mixture was allowed to reach 0 °C. After 3 hr at 0 °C, the reaction mixture was diluted
 with ethyl acetate (50ml) and the solution left at room temperature for 5 min. This
 solution was washed subsequently with 10 % aqueous K₂CO₃ solution (20 ml) and
 with brine (20 ml). The organic layer was dried over magnesium sulfate and the
 solvent removed in vacuo. The residue was chromatographed on silica gel (4g, 63 -
 35 200 μ m) using chloroform-methanol (9 : 1) to give the title p-nitrobenzyl ester as a

pale yellow non-crystalline solid (yield 89 %). IR spectrum in CH_2Cl_2 : 3600, 3050, 2900, 1770, 1710 (shoulder), 1685, 1605, 1520, 1345, 1200, 1135 cm^{-1} .



15 Potassium (4R,5S,6S)-3-((2,3-dioxo-4-ethyl-piperazinyl)methylthio)-6-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

To 10 % palladium on carbon (90 mg), prehydrogenated at 0 °C in a two phase mixture of ethyl acetate (4 ml) and KHCO_3 (10,6 mg, 0.106 mmol) in water (3 ml) a solution of p-nitrobenzyl (4R,5S,6S)-3-((2,3-dioxo-4-ethyl-piperazinyl)methylthio)-6-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylate (76 mg, 0.14 mmol) in ethyl acetate (4 ml) was added by a syringe. The mixture was then hydrogenated at ambient pressure and 0 °C. After 70 min the uptake of hydrogen (10.8 ml) became very slow. Additional catalyst (30 mg) was added and

25 hydrogenation was continued for additional 45 min. Additional hydrogen (6.6 ml) was consumed. The catalyst was removed by filtration, washed with ethyl acetate (2ml) and water (1 ml) and the filtrate transferred to a separatory funnel. The aqueous layer was collected and the organic layer extracted with a solution of KHCO_3 (3.6 mg, 0.036 mmol) in water (1 ml). The combined aqueous solutions were evacuated in order to

30 remove residual ethyl acetate and then lyophilized at -30 °C in high vacuo (0.001 mm) to give the pure title compound as white powder (yield 65 %). UV-spectrum in water $\lambda_{\text{max}} = 292 \text{ nm}$ ($\epsilon = 8000$), 222 nm ($\epsilon = 11200$). NMR-spectrum in D_2O (int. standard $\text{Me}_3\text{CD}_2\text{CD}_2\text{COONa}$): 1.1 - 1.3 (m, 6H), 1.30 (d, 3H, $J = 6 \text{ Hz}$), 3.50 (m, 6H), 3.4 - 3.8 (m, 8H), 4.18 (m, 1H), 4.25 (m, 1H), 4.30 and 5.30 (ABq, 2H, $J = 14 \text{ Hz}$, $\text{N-CH}_2\text{-S}$) ppm.

35

Example 14

Biological Activity

5 I. In Vitro Antibacterial Activity

Table I shows inhibition diameters in mm after investigation of 10 µg of the representative antibiotics (plate test results). The tests were carried out in sterile polypropylene dishes (diameter 8.5 cm) containing 10 ml of Difco Nutrient Agar. Inhibition was recorded after 18 hrs at 37 °C (inoculum ca. 10⁻⁵ cells).

Table I

	lb	lc	le	lf
Staph. aureus DSM 1104	39	39	36	33
Staph. aureus resistant	35	35	32	30
15 Staph. aureus 25768	28	26	27	25
Staph. aureus Innsbruck	9	8	-	12
Escherichia coli DSM 1103	30	30	32	27
Escherichia coli TEM 1	33	33	34	33
20 Enterobacter cloacae DSM 30054	26	25	27	23
Enterococcus	21	21	18	20
Pseudomonas aer. DSM 1117	27	25	16	18
Pseudomonas aer. resistant	17	13	-	14

25 2. β-Lactamase inhibition activity against isolated (cell free) enzymes

Table II shows the β-lactamase inhibition activity (mol per liter) of the representative compounds according to the invention as determined by the nitrocefin method. IC₅₀ values were determined in a 1 cm UV cell at 37 °C after a 15 min preincubation period of enzyme and the inhibitor.

Table II

IC₅₀ (mol per liter)

compound	Penicillinase from <i>E. coli</i> TEM 1	β -Lactamase from <i>Enterobacter cloacae</i>
la	2×10^{-7}	4×10^{-9}
lb	5.5×10^{-7}	8.5×10^{-9}
le	3×10^{-7}	6×10^{-9}

3. β -Lactamase inhibition activity against resistant bacteria

Table III shows the antibacterial activity (MIC, μg per ml) of ceftazidime (CAZ) without and in combination with representative compound la (potassium salt).

Table III

bacterial strain	enzyme	CAZ (μg per ml)	CAZ + 1a (μg per ml)
<i>E. cloacae</i> EB 131	Type 1 Ceph'ase	>64	2 + 1
<i>K. pneumoniae</i> KL 140	CAZ-ase	>64	2 + 1
<i>K. pneumoniae</i> KL 141	CAZ-ase	>64	64 + 0.12
<i>E. coli</i> EC 227	CAZ-ase	>64	0.25 + 0.5
<i>E. coli</i> EC 228	CAZ-ase	16	1 + 0.5
<i>E. coli</i> EC 225	TEM-5	64	2 + 0.5

4. Stability in phosphate buffer

Table IV shows the half-lives of hydrolysis (in hrs) of the representative compounds in physiological phosphate buffer pH 7.4 and 37 °C as determined by the UV method.

Table IV

compound	half-life (hrs)
la	50
lb	50
lc	35
ld	50
le	40
lf	16
lg	42

5. Oral activity

Table V shows the plasma level and half-life in mice after oral application of compound la (potassium salt) according to the invention (dose 25 mg per kg).

Table V

compound	Plasma level (μ g per ml) 10 min after application	Approximative serum half-life (min)
la	5.6	25

6. Cytotoxicity

Table VI shows the cytotoxicity in *Sacharomyces cerevisiae* of the representative compounds (1.0 mg) as determined by the agar diffusion method. Sterile PP dishes of 8.5 cm diameter containing 10 ml of yeast and mold agar were used. Cytotoxicity was recorded after a 16 hrs incubation period at 30 °C (inoculum approx. 10^5 cells).

Table VI

compound	inhibition diameter (mm)
lb	0
le	0
lf	0

Example 15

10 Production of pharmaceutical preparations

A unit dose form is prepared by mixing 60 mg of (4R,5S,6S)-3-((2-aminoethoxy)methylthio)-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (lb) with 20 mg of lactose and 5 mg of magnesium stearate and the 85 mg of mixture are added to a No. 3 gelatin capsule. Similarly, if more active constituents and less lactose are used, other dose forms may be prepared and filled into No. 3 gelatin capsules. Similarly, larger gelatin capsules and also compressed tablets and pills may also be produced. The following examples illustrate the production of pharmaceutical preparations.

20

Tablet (for oral application)

(4R,5S,6S)-3-((2-Aminoethoxy)methylthio)-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (lb)	120 mg
Corn starch	6 mg
Magnesium stearate	232 mg
Dicalcium phosphate	192 mg
Lactose	250 mg

30 The active constituent is mixed with the dicalcium phosphate, lactose and about half of the corn starch and coarse-sieved. It is dried in high vacuum and again sieved through sieves having mesh widths of 1.00 mm (No. 16 screens). The rest of the corn starch and the magnesium stearate is added and the mixture is pressed to give tablets which each weight 800 mg and have a diameter of about 1.27 cm (0.5 in.).

Parenteral solutionAmpoule

- | | | |
|---|---|--------|
| 5 | (4R,5S,6S)-3-((2-Aminoethoxy)methylthio)-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (Ib) | 250 mg |
| | Sterile water (is added from a separate ampoule using a syringe immediately before use) | 4 ml |

10 Ophthalmic solution

- | | | |
|----|---|-------|
| | (4R,5S,6S)-3-((2-Aminoethoxy)methylthio)-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (Ib) | 50 mg |
| | Hydroxypropylmethylcellulose | 5 mg |
| 15 | Sterile water (is added from a separate ampoule using a syringe immediately before use) | 1 ml |

Otic solution

- | | | |
|----|---|--------|
| 20 | (4R,5S,6S)-3-((2-Aminoethoxy)methylthio)-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (Ib) | 50 mg |
| | Benzalkonium chloride | 0.1 mg |
| | Sterile water (is added from a separate ampoule using a syringe immediately before use) | 1 ml |
| 25 | | |

Topical cream or ointment

- | | | |
|----|---|--------|
| | (4R,5S,6S)-3-((2-Aminoethoxy)methylthio)-((1'R)-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (Ib) | 100 mg |
| 30 | Polyethylene glycol 4000 | 400 mg |
| | Polyethylene glycol 400 | 1.0 g |

The active component in the above preparations can be mixed alone or together with other biologically active components, for example with other antibacterial agents such as a penicillin or cephalosporins or with other therapeutic agents, such as probenecid.

It is understood that the specification and examples are illustrative but not limitative of the present invention and that other embodiments within the spirit and scope of the invention will suggest themselves to those skilled in the art.

5

10

15


20

25

30

Claims

1. Compounds of the structural formula I



I

and their pharmaceutically acceptable salts, esters and amide derivatives, in which R¹ denotes hydrogen, hydroxymethyl or 1-hydroxyethyl, R² denotes hydrogen or methyl and R³ denotes a pharmaceutically acceptable group which is bonded to the remaining part of the molecule by an oxygen-carbon single bond or a nitrogen-carbon single bond and which is selected from the group comprising substituted or unsubstituted: alkoxy, alkenyloxy, alkinyloxy, cycloalkoxy, N-heterocyclyl, heterocyclyloxy, heterocyclylcarbonyloxy, heterocyclylthiocarbonyloxy, acyloxy, thioacyloxy, alkoxycarbonyloxy, carbamoyloxy, thiocarbamoyloxy, heterocyclyloxy carbonyloxy, heterocyclyloxythiocarbonyloxy, N-heterocyclyl carbamoyloxy, N-heterocyclylthiocarbamoyloxy, heterocyclylcarbonylamino, heterocyclylthiocarbonylamino, heterocyclyloxy carbonylamino, acylamino, alkoxycarbonylamino, alkoxythiocarbonylamino, thioacylamino, N-heterocyclyl carbamoylamino, N-heterocyclylthiocarbamoylamino, carbamoylamino, thiocarbamoylamino, imidoylamino, guanidino, N-heterocyclyl-alkoxycarbonylamino, N-heterocyclyl-alkylthiocarbonylamino and N-sulfonylamino where the foregoing alkyl, alkenyl, alkynyl, acyl, thioacyl or imidoyl molecule parts contain 1 to 6 carbon atoms and the heterocyclyl moiety is monocyclic or bicyclic and contains 3 to 10 ring atoms, of which one or more are selected from the series comprising: oxygen, sulphur and nitrogen and where the substituents of the above-mentioned groups R³ may be: alkyl, acyl, thioacyl, heterocyclyl, hydroxyl, hydroxyalkyl, alkoxy, hydroxyalkoxy, aminoalkoxy, amidinoalkoxy, guanidinoalkoxy, acyloxy, heterocyclyloxy, alkylheterocyclyloxy, hydroxyalkylheterocyclyloxy, aminoalkylheterocyclyloxy, carbamoyl, alkylcarbamoyl,


dialkylcarbamoyl, carbamoyloxy, alkylcarbamoyloxy, dialkylcarbamoyloxy, thiocarbamoyl, alkylthiocarbamoyl, dialkylthiocarbamoyl, thiocarbamoyloxy, alkylthiocarbamoyloxy, dialkylthiocarbamoyloxy, mercapto, alkylthio, hydroxyalkylthio, aminoalkylthio, monoalkylaminoalkylthio, dialkylaminoalkylthio, amidinoalkylthio, 5 acylthio, heterocyclylthio, alkylheterocyclylthio, hydroxyalkylheterocyclylthio, aminoalkylheterocyclylthio, carbamoylthio, monoalkylcarbamoylthio, dialkylcarbamoylthio, thiocarbamoylthio, alkylthiocarbamoylthio, dialkylcarbamoylthio, amino, monoalkylamino, hydroxyalkylamino, aminoalkylamino, dialkylamino, oxo, oximino, or alkylimino, imidoylamino, alkylimidoylamino, dialkylimidoylamino, 10 tetraalkylammonium, cycloalkylamino, heterocyclylamino, alkylheterocyclylamino, heterocyclylcarbonylamino, alkylheterocyclylcarbonylamino, acylamino, amidino, monoalkylamidino, dialkylamidino, guanidino, alkylguanidino, dialkylguanidino, carbamoylamino, thiocarbamoylamino, alkylcarbamoylamino, thiocarbamoylamino, alkylthiocarbamoylamino, nitro, chlorine, bromine, fluorine, iodine, azido, cyano, 15 alkylsulphinyl, alkylsulphonyl, sulphonamido, sulphamoyloxy, alkylsulphamoyloxy, alkylsulphonyloxy or sulpho, sulphoxy, carboxamido, N-monoalkylcarboxamido, N,N-dialkylcarboxamido or carboxy, where the substituents, independently of one another, occur once or several times and their alkyl moiety contains 1 to 6 carbon atoms, and where the heterocyclic moiety is monocyclic or bicyclic and contains 3 to 10 ring 20 atoms, of which one or more are selected from the series comprising: oxygen, sulphur and nitrogen.

2. Compounds according to Claim 1, characterized in that R¹ denotes hydrogen, hydroxymethyl or 1-hydroxyethyl, R² denotes hydrogen or methyl and R³ is selected 25 from the group comprising substituted or unsubstituted alkoxy, heterocyclyloxy, acyloxy, carbamoyloxy, N-heterocyclyl, acylamino, carbamoylamino, imidoylamino where the foregoing alkyl, acyl, thioacyl, or imidoyl molecule parts contain 1 to 3 carbon atoms and the heterocyclyl moiety is monocyclic and contains 3 to 6 ring atoms, of which one or more are selected from the series comprising : oxygen, 30 sulphur and nitrogen and where the substituents of the above-mentioned groups R³ may be: alkyl, acyl, thioacyl, heterocyclyl, hydroxyl, hydroxyalkyl, alkoxy, hydroxyalkoxy, aminoalkoxy, amidinoalkoxy, guanidinoalkoxy, acyloxy, heterocyclyloxy, alkylheterocyclyloxy, hydroxyalkylheterocyclyloxy, aminoalkylheterocyclyloxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, 35 carbamoyloxy, alkylcarbamoyloxy, dialkylcarbamoyloxy, thiocarbamoyl,

alkylthiocarbamoyl, dialkylthiocarbamoyl, thiocarbamoyloxy, alkylthiocarbamoyloxy, dialkylthiocarbamoyloxy, mercapto, alkylthio, hydroxyalkylthio, aminoalkylthio, monoalkylaminoalkylthio, dialkylaminoalkylthio, amidinoalkylthio, acylthio, heterocyclylthio, alkylheterocyclylthio, hydroxyalkylheterocyclylthio, aminoalkylheterocyclylthio, carbamoylthio, monoalkylcarbamoylthio, dialkylcarbamoylthio, thiocarbamoylthio, alkylthiocarbamoylthio, dialkylcarbamoylthio, amino, monoalkylamino, hydroxyalkylamino, aminoalkylamino, dialkylamino, oxo, oximino, or alkylimino, imidoylamino, alkylimidoylamino, dialkylimidoylamino, tetraalkylammonium, cycloalkylamino, heterocyclylamino, alkylheterocyclylamino, heterocyclylcarbonylamino, alkylheterocyclylcarbonylamino, acylamino, amidino, monoalkylamidino, dialkylamidino, guanidino, alkylguanidino, dialkylguanidino, carbamoylamino, thiocarbamoylamino, alkylcarbamoylamino, thiocarbamoylamino, alkylthiocarbamoylamino, nitro, chlorine, bromine, fluorine, iodine, azido, cyano, alkylsulphinyl, alkylsulphonyl, sulphonamido, sulphamoyloxy, alkylsulphamoyloxy, alkylsulphonyloxy or sulpho, sulphony, carboxamido, N-monoalkylcarboxamido, N,N-dialkylcarboxamido or carboxy, where the substituents, independently of one another, occur once or several times and their alkyl moiety contains 1 to 6 carbon atoms, and where the heterocyclic moiety is monocyclic and contains 3 to 6 ring atoms, of which one or more are selected from the series comprising: oxygen, sulphur and nitrogen.


3. Compounds according to Claim 1, characterized in that R^1 denotes hydrogen, hydroxymethyl or 1-hydroxymethyl, R^2 denotes hydrogen or methyl and R^3 is selected from the group comprising: substituted alkoxy, acylamino, alkylcarbamoylamino, alkoxy-carbamoylamino, N-heterocyclyl and imidoylamino, where the foregoing alkyl, acyl or imidoyl molecule parts contain 1 to 3 carbon atoms and the heterocyclyl moiety is monocyclic and contains 3 to 6 ring atoms, of which one or more are selected from the series comprising: oxygen, sulphur and nitrogen and where the substituents of the above-mentioned groups R^3 are basic groups such as amino, alkylamino, dialkylamino, imidoyl, amidino and guanidino, in which the alkyl, amidino and imidoyl parts contain 1 to 3 carbon atoms.

4. Compounds according to Claim 1, characterized in that R^1 denotes 1-hydroxyethyl, R^2 denotes methyl and R^3 is selected from the group comprising




5. A pharmaceutical composition comprising an antibacterial effective amount of at least one compound of any one of Claims 1 to 4 and a pharmaceutically acceptable carrier or diluent.
- 15 6. A process for preparing the composition of Claim 5, which comprises incorporating an antibacterial effective amount of at least one compound of any one of Claims 1 to 4 into a pharmaceutically acceptable carrier or diluent.
- 20 7. A method of inhibiting bacteria in a patient in need thereof, which comprises administering to said patient an effective amount of at least one compound of any one of Claims 1 to 4.
- 25 8. A pharmaceutical composition comprising an effective amount for β -lactamase inhibition of at least one compound of any one of Claims 1 to 4, a conventional β -lactam antibiotic and a pharmaceutically acceptable carrier or diluent.
9. A process for preparing the composition of Claim 8, which comprises incorporating an effective amount of at least one compound of any one of Claims 1 to 4 and a conventional β -lactam antibiotic into a pharmaceutically acceptable carrier or diluent.
- 30 10. A method of inhibiting β -lactamase in a patient in need thereof, which comprises administering to said patient an effective amount of at least one compound of any one of Claims 1 to 4 and a conventional β -lactam antibiotic.

11. A process for preparing the compounds of Claims 1 to 4, which comprises reacting a compound of formula




10 wherein R^1 and R^2 are as defined in Claim 1, X is a leaving group and Y is a conventional carboxy protecting group, with a thiol of formula



15 or an organic or inorganic salt thereof, wherein R^3 is as defined in Claim 1.

12. A process for preparing the compounds of Claims 1 to 4, which comprises reacting with a deprotecting agent a compound of formula



25 wherein R^1 , R^2 and R^3 are as defined in Claim 1 and Y is a conventional carboxy protecting group.

30

35

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/EP 99/05295

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D477/20 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 079 244 A (SHIONOGI & CO) 18 May 1983 (1983-05-18) claims	1-12
Y	EP 0 168 707 A (MERCK & CO INC) 22 January 1986 (1986-01-22) claims	1-12
Y	EP 0 169 410 A (MERCK & CO INC) 29 January 1986 (1986-01-29) claims	1-12
	--- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 October 1999

Date of mailing of the international search report

08/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Chouly, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/05295

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>CHEMICAL ABSTRACTS, vol. 110, no. 23, 5 June 1989 (1989-06-05) Columbus, Ohio, US; abstract no. 212493, TAMAI S. ET AL: "Preparation of (1R,5S,6S)-2-[(3-substituted imidazolium-1-yl)alkylthio]-6-[(R)-1-hydro xyethyl]-1-methyl-carbapenem-3-carboxylate s as antibacterial agents " XP002119929 abstract & JP 63 255283 A (LEDERLE LTD.) 21 October 1988 (1988-10-21) ----</p>	1-12
A	<p>EP 0 481 511 A (SQUIBB BRISTOL MYERS CO) 22 April 1992 (1992-04-22) claims ----</p>	1-12
A	<p>CHEMICAL ABSTRACTS, vol. 103, no. 15, 14 October 1985 (1985-10-14) Columbus, Ohio, US; abstract no. 123260, "Thienamycin derivatives" XP002119930 abstract & JP 60 054387 A (MERCK AND CO., INC.) 28 March 1985 (1985-03-28) -----</p>	1-12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/05295

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 7, 10
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 7, 10
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/05295

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0079244	A	18-05-1983	JP 58124785 A	25-07-1983
			JP 59039895 A	05-03-1984
			JP 58083692 A	19-05-1983
			JP 58116485 A	11-07-1983
			GB 2116540 A,B	28-09-1983
			US 4556517 A	03-12-1985
			US 4448723 A	15-05-1984

EP 0168707	A	22-01-1986	CA 1273013 A	21-08-1990
			DK 297685 A	03-01-1986
			ES 544754 A	16-09-1986
			JP 61063679 A	01-04-1986

EP 0169410	A	29-01-1986	AT 85978 T	15-03-1993
			CA 1285940 A	09-07-1991
			DE 3587112 A	08-04-1993
			DK 297485 A	14-03-1986
			ES 544753 A	16-09-1986
			JP 61083184 A	26-04-1986

JP 63255283	A	21-10-1988	NONE	

EP 0481511	A	22-04-1992	US 5116833 A	26-05-1992
			AU 636249 B	22-04-1993
			AU 8595091 A	30-04-1992
			CA 2052942 A	20-04-1992
			FI 914874 A,B,	20-04-1992
			JP 4282383 A	07-10-1992
			PT 99285 A,B	31-08-1992

JP 60054387	A	28-03-1985	NONE	
